ProShares Ultra NASDAQ Biotechnology
36 hedge funds and large institutions have $18.2M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
98% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $7.35M
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
22% more capital invested
Capital invested by funds: $14.8M → $18.2M (+$3.34M)
20% more funds holding
Funds holding: 30 → 36 (+6)
0.85% less ownership
Funds ownership: 7.55% → 6.7% (-0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$939K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$510K |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$455K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$386K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$215K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$1.21M |
| 2 |
HF
HRT Financial
New York
|
-$593K |
| 3 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$502K |
| 4 |
UMC
United Maritime Capital
New York
|
-$175K |
| 5 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$137K |
BIB Hedge Fund Activity: Q2 2021 in Review
36 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2021, worth a combined $18.2M — up 22% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BIB positions and 6 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $939K. The largest seller was Old Mission Capital, cutting an estimated $1.21M.
- 36 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2021, up from 30 in Q1 2021.
- Funds reported $18.2M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2021, up 22% quarter-over-quarter.
- 12 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2021 and 6 closed out, a net change of +6 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2021 was Jane Street, an estimated $939K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2021 was Old Mission Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2021.